Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RCUS 
Arcus Biosciences Inc (RCUS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/25/2025: RCUS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -75.13% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/25/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 816.03M USD | Price to earnings Ratio - | 1Y Target Price 32.55 |
Price to earnings Ratio - | 1Y Target Price 32.55 | ||
Volume (30-day avg) 1250759 | Beta 1.36 | 52 Weeks Range 7.50 - 18.98 | Updated Date 04/1/2025 |
52 Weeks Range 7.50 - 18.98 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -109.69% | Operating Margin (TTM) -396.15% |
Management Effectiveness
Return on Assets (TTM) -17.26% | Return on Equity (TTM) -59.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -101962637 | Price to Sales(TTM) 3.16 |
Enterprise Value -101962637 | Price to Sales(TTM) 3.16 | ||
Enterprise Value to Revenue 2.34 | Enterprise Value to EBITDA 3.96 | Shares Outstanding 105841000 | Shares Floating 65841832 |
Shares Outstanding 105841000 | Shares Floating 65841832 | ||
Percent Insiders 5.52 | Percent Institutions 83.65 |
Analyst Ratings
Rating 4.38 | Target Price 33.2 | Buy 2 | Strong Buy 8 |
Buy 2 | Strong Buy 8 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Arcus Biosciences Inc
Company Overview
History and Background
Arcus Biosciences, Inc. was founded in 2015. It is a clinical-stage biopharmaceutical company focused on creating differentiated cancer therapies.
Core Business Areas
- Oncology: Developing immuno-oncology therapies and combinations to treat various cancers.
Leadership and Structure
The company is led by a team of experienced pharmaceutical executives and scientists. Organizational structure includes research, development, and commercial teams.
Top Products and Market Share
Key Offerings
- Domvanalimab: An anti-TIGIT antibody in clinical trials for lung and upper gastrointestinal cancers. Competitors include Roche (TIGIT inhibitor development).
- Etrilimab: An anti-PD-1 antibody being investigated in various clinical trials, often in combination therapies. Competitors are Merck's Keytruda and Bristol Myers Squibb's Opdivo.
- Quemliclustat: Small molecule A2a/A2b adenosine receptor antagonist. Competitors include Corvus Pharmaceuticals (CORV).
Market Dynamics
Industry Overview
The oncology market is rapidly growing, driven by increasing cancer prevalence and advancements in immunotherapies and targeted treatments.
Positioning
Arcus is positioned as an innovator in immuno-oncology, focusing on combination therapies. It aims to improve treatment outcomes by targeting multiple immune checkpoints.
Total Addressable Market (TAM)
The global oncology market is estimated to reach hundreds of billions of dollars. Arcus is targeting specific segments within this market, positioning it to capture a portion of this vast opportunity.
Upturn SWOT Analysis
Strengths
- Strong pipeline of novel immuno-oncology candidates
- Experienced management team
- Strategic collaborations with larger pharmaceutical companies
Weaknesses
- Reliance on clinical trial success
- High cash burn rate
- Competition from established players
Opportunities
- Potential for breakthrough therapies in cancer treatment
- Expansion of pipeline through internal research and acquisitions
- Partnering opportunities with other biotech and pharma companies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other immuno-oncology therapies
- Changes in healthcare policy
Competitors and Market Share
Key Competitors
- MRK
- BMY
- ROCHE.SW
Competitive Landscape
Arcus faces intense competition from larger pharmaceutical companies with established immuno-oncology franchises. Its competitive advantage lies in its innovative pipeline and strategic collaborations.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is driven by the advancement of its clinical pipeline.
Future Projections: Future growth depends on clinical trial successes, regulatory approvals, and commercialization of its products. Analyst estimates vary widely based on these factors.
Recent Initiatives: Arcus is actively pursuing strategic collaborations and partnerships to expand its pipeline and accelerate development programs.
Summary
Arcus Biosciences is a clinical-stage biotech with a promising immuno-oncology pipeline, facing a high-risk, high-reward scenario. Success depends on positive clinical trial results and effective partnerships. The company's high cash burn requires careful management, and the competitive landscape is intense.
Similar Companies
- MRK
- BMY
- REGN
Sources and Disclaimers
Data Sources:
- Company Filings (SEC), Investor Presentations, Analyst Reports, ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arcus Biosciences Inc
Exchange NYSE | Headquaters Hayward, CA, United States | ||
IPO Launch date 2018-03-15 | Co-Founder, Chairman & CEO Dr. Terry J. Rosen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 627 | Website https://www.arcusbio.com |
Full time employees 627 | Website https://www.arcusbio.com | ||
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.